STSaleh Tabatabaei

Saleh Tabatabaei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saleh Tabatabaei has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CT-Defined Osteosarcopenia Is Associated with Mortality in Metastatic Prostate Cancer: A Longitudinal Analysis of Opportunistic CT Imaging

    by Tayler D. Ross, Saleh Tabatabaei, Rose Yakubov, Urban Emmenegger, Cari Whyne, Michael Hardisty

    Background/Objectives: In metastatic prostate cancer, loss of bone density (osteoporosis), muscle quantity and quality (sarcopenia) may contribute to fractures, falls, and mortality. Unfortunately, their longitudinal assessment is poorly characterized. In prostate cancer, ageing, advanced disease, and cancer treatments may accelerate bone and muscle loss. This study assessed longitudinal computed tomography-derived musculoskeletal biomarkers in metastatic prostate cancer and the association between baseline osteosarcopenia and mortality. Methods: This retrospective single-centre cohort included 437 patients, 3595 muscle computed tomography (CT) assessments and 2944 bone CT assessments. An automated deep-learning pipeline quantified lumbar trabecular bone mineral density (BMD), psoas muscle volume (PV), and psoas muscle density. Osteosarcopenia was defined as concurrent osteoporosis (BMD < 135 Hounsfield Units (HU)) and sarcopenia (volumetric psoas muscle index (vPMI) < 30). Patient-aware mixed-effects models characterized biomarker trends and reverse-time analysis. Kaplan–Meier analysis and Cox proportional-hazards regressions were utilized to assess mortality. Results: Baseline osteosarcopenia affected 75 patients (17.2%). Psoas density decreased by 1.569 HU/year (95% confidence interval (CI) −1.703 to −1.434 HU/yr). Nonlinear models estimated mean declines in psoas volume (−6.42 cm3/year) and bone density (−6.01 HU/year). Among deceased patients, modelled final-year declines showed −12.57% in psoas density and −10.28% in psoas volume. Baseline osteosarcopenia was associated with higher all-cause mortality (Hazard Ratio (HR) 1.611; 95% CI 1.134–2.288; p = 0.008). Conclusions: Osteosarcopenia is common and progressive in metastatic prostate cancer, and muscle loss accelerates near death. Baseline osteosarcopenia independently identifies patients at increased mortality risk. CT imaging provides a scalable approach for longitudinal assessment of musculoskeletal health and offers clinically important information without additional patient burden.

  • Open Access

    Osteosarcopenia Predicts Mortality in Metastatic Prostate Cancer: A Longitudinal Analysis of Opportunistic CT Imaging

    by Tayler D. Ross, Saleh Tabatabaei, Rose Yakubov, Urban Emmenegger, Cari Whyne, Michael Hardisty

    Background/Objectives: Osteoporosis and sarcopenia are associated with fractures, falls, and mortality. In prostate cancer, aging, advanced disease, and androgen deprivation therapy may accelerate concurrent bone and muscle loss. This study characterized longitudinal CT-derived musculoskeletal biomarkers in metastatic prostate cancer and evaluated the association between baseline osteosarcopenia and overall survival. Methods: This retrospective single-centre cohort included patients treated from 2009 to 2022, with follow-up imaging through 2024. An automated deep-learning pipeline quantified lumbar trabecular bone mineral density (BMD), psoas muscle volume (PV), psoas muscle density (PD), and volumetric psoas muscle index (vPMI). Osteosarcopenia was defined as concurrent osteoporosis (BMD < 135 HU) and sarcopenia (vPMI < 30). Survival from baseline CT was assessed using Kaplan-Meier analysis and multivariable Cox regression. Results: Among 437 patients with 3389 CT scans, osteoporosis, sarcopenia, and osteosarcopenia increased from 29.6%, 46.9%, and 17.2% at baseline to 54.0%, 82.8%, and 45.5% at final imaging. BMD declined by 2.1-3.7% annually, PD by 3.2-3.9%, and PV by 3.6-4.6% (all p < 0.0001). In the final year of life, PD declined by 12.0% and PV by 9.3%. Baseline osteosarcopenia remained independently associated with mortality after adjustment for age, time from diagnosis to baseline CT, PSA, and Gleason risk group (HR 2.11, 95% CI 1.50-2.99; p < 0.001). Conclusions: Osteosarcopenia is common and progressive in metastatic prostate cancer, and muscle loss accelerates near death. Baseline osteosarcopenia independently identifies patients at increased mortality risk. Automated analysis of routine surveillance CT may enable longitudinal musculoskeletal assessment and prognostic risk stratification.

  • AN AI-ENABLED STUDY ON OSTEOSARCOPENIA PROGRESSION IN PROSTATE CANCER PATIENTS USING MUSCULOSKELETAL IMAGING BIOMARKERS

    by S. Tabatabaei, T. Ross, G. Klein, T. Vujovic, K. Rahman, J. Finkelstein, C. Whyne, U. Emmenegger, M. Hardisty

    Osteosarcopenia is a musculoskeletal (MSK) condition that is a combination of osteopenia/osteoporosis (decreased bone mineral density - BMD) and sarcopenia (decreased skeletal muscle mass and strength). Both conditions are prevalent in prostate cancer cohorts. Advanced therapeutics extend survival in cancer patients, but the prolonged period of active disease and treatment have irreversible, deleterious impacts on MSK health due to the progressive nature of osteosarcopenia. Osteosarcopenia can lead to increased falls, fractures, decreases in quality of life and poor patient outcomes. Traditionally, osteopenia and sarcopenia were studied separately, leaving combined effects and interactions underexamined. Additionally, prior studies rely on single time point evaluations with Dual-Energy X-ray Absorptiometry (DEXA) and 2D Computed Tomography (CT) scans, neglecting temporal progression. To retrospectively quantify osteosarcopenia progression in advanced prostate cancer patients using imaging biomarkers. Sarcopenia will progress over time with decreases in muscle quality and quantity, while BMD may rise due to sclerotic metastatic lesions. MSK biomarkers were calculated for patients treated with systemic therapy at Sunnybrook Odette Cancer Centre from 2009 to 2021 using opportunistic prostate cancer surveillance images (REB#1862). Lumbar Spine 3D CT scans were reconstructed to a higher resolution of 1mm isotropic voxel size from diagnostic axial, sagittal, and coronal reconstructions using a custom iterative approach. The biomarker extraction pipeline segmented lumbar vertebral bodies (L1-L5) and psoas muscles using a combination of convolutional neural network architectures. The superior and inferior boundary of the psoas muscle were set from L2/L3 to L4/L5 disc mid-points based on vertebral segmentations. BMD of the lumbar vertebral bodies and the psoas muscle volume and density, quantified using Hounsfield units, were extracted. Our analysis included 142 male patients (age: mean=71 years, range=44-90 years) with 475 CT scans with average follow up of 1034 days (range=45-3284 days). Throughout this period, BMD increased (17.1%, STD=48%), psoas volume decreased (5.7%, STD=34.9%), and psoas density decreased (17.9% STD=46.7%). BMD was stable or decreased for 51.8% of subjects, while 25.9% of subjects had a >30% BMD increase. Psoas density and volume were decreased in two out of three subjects. Moderate to weak correlations were found for the temporal rate of change of the MSK biomarkers (psoas volume vs. BMD R2=-0.29, psoas density vs. BMD R2=-0.10, psoas volume vs. psoas density R2=-0.46, all p This study quantifies marked longitudinal changes in osteosarcopenia biomarkers in advanced prostate cancer patients. The majority of patients experienced sarcopenia progression despite prostate cancer treatments, highlighting the potential impacts of advanced therapeutics and disease progression on MSK health. The BMD increases were measured secondary to sclerotic metastatic lesions. The correlations between the rate of change of MSK biomarkers indicate a complex interaction between bone and muscle health in prostate cancer patients. This study showed greater deterioration of BMD at non-metastatic levels and of muscle quality and quantity in prostate cancer patients compared to previous reports, likely attributable to longer follow-up. The osteosarcopenia quantitative 3D imaging biomarkers are more sensitive to changes than 2D biomarkers for longitudinal assessment. These methods can track osteosarcopenia progression and monitor metastatic progression and other MSK health-impacting conditions.

  • Open Access

    Characterization of Osteosarcopenia in Spinal Metastases Patients to Be Treated with Stereotactic Body Radiotherapy Using Quantitative Image-Based AI-Derived Biomarkers

    by Yessica Castano Sainz, Stephen Chen, Saleh Tabatabaei, Tayler Declan Ross, Cari Whyne, Jay Detsky, Arjun Sahgal, Michael Hardisty